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Abstract
Background: Vaccination is a cost-effective and life-saving intervention. Recently several new, but more expensive
vaccines have become part of immunization programmes in low and middle income countries (LMIC). Monitoring
vaccine wastage helps to improve vaccine forecasting and minimise wastage. As the costs of vaccination increases
better vaccine management is essential. Many LMIC however do not consistently monitor vaccine wastage.
Methods: We conducted two surveys in health facilities in rural and urban Gambia; 1) a prospective six months
survey in two regions to estimate vaccine wastage rates and type of wastage for each of the vaccines administered
by the Expanded programme on Immunization (EPI) and 2) a nationwide cross sectional survey of health workers
from randomly selected facilities to assess knowledge, attitude and practice on vaccine waste management. We
used WHO recommended forms and standard questionnaires. Wastage rates were compared to EPI targets.
Results: Wastage rates for the lyophilised vaccines BCG, Measles and Yellow Fever ranged from 18.5–79.0%, 0–30.
9% and 0–55.0% respectively, mainly through unused doses at the end of an immunization session.
Wastage from the liquid vaccines multi-dose/ single dose vials were minimal, with peaks due to expiry or breakage
of the vaccine diluent.
We interviewed 80 health workers and observed good knowledge. Batching children for BCG was uncommon
(19%) whereas most health workers (73.4%) will open a vial as needed.
Conclusion: National projected wastage targets were met for the multi-dose/single dose vials, but for lyophilised
vaccines, the target was only met in the largest major health facility.
Background
Vaccination will save more than 20 million lives in low
and middle income countries between 2001 2020 [1]. In
recent years a number of new vaccines have been added
to national vaccination programmes and consequently
the cost per fully immunised child has increased consid-
erably [2–4]. These growing costs make the considerate
use of vaccines pressing and interest to minimise vaccine
wastage has risen.
Vaccine wastage, usually measured as rate, is the pro-
portion of vaccine doses supplied but not administered.
Wastage is categorized primarily into two types: a) wast-
age of the remaining doses in opened vials at the end of
an immunisation session, and b) wastage from unopened
vials generally due to problems related to the cold chain,
breakage or expiry [5, 6]. A number of factors are known
to influence vaccine wastage. These broadly include the
vaccines themselves, syringes, logistics, immunisation
practices, and national policies [6].
In 2005, the WHO estimated that approximately half
of the vaccines produced globally are wasted and there-
fore recommended that countries strengthen local vac-
cine wastage monitoring [6]. Parmar et al. reported in
2010 that only 19 (26%) of 72 GAVI eligible countries
had submitted to WHO wastage data that could be ana-
lysed [7]. In the absence of local data, countries use
WHO projected wastage rates to estimate their vaccine
needs [8].
Due to restricted cold storage capacity in many devel-
oping countries, multi-dose vials are commonly used. In
2014, WHO revised its multi-dose vial policy (MDVP)
to advice countries on minimising vaccine wastage while
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ensuring vaccine safety [9]. Under the policy, multi-dose
vials with preservatives may be kept for up to 28 days
after opening in contrast to the lyophilised vaccines,
which do not contain preservatives, and should be dis-
carded 6 h after reconstitution [9].
Despite the recommendations and renewed policy,
recent data on vaccine wastage are lacking and
published studies have relied primarily on mathemat-
ical models [10]. In this study, we prospectively quan-
tified wastage rates and type for the vaccines used in
the Gambian Expanded Programme on Immunization
(EPI) and assessed the knowledge, attitude and practice
(KAP) of Gambian health workers on general knowledge
on immunisation and vaccine waste management.
Methods
Background setting
The Gambia a small country in West-Africa, had a popu-
lation of about two million and a birth cohort of 86,990
live births in 2016. The national EPI was launched in 1979
initially with six vaccines and since then several other vac-
cines have been introduced (Table 1). Vaccination occurs
mainly via fixed based and mobile outreach clinics, with
occasional campaigns and national immunisation days as
needed. Data collected from health and demographic
surveillance systems between 2005 and 2012 showed
coverage of Bacillus Calmette–Guérin (BCG) and
Diphtheria-Pertussis-Tetanus (DPT3) to be > 95 and >
80% respectively across all regions in the country [11]. Full
immunisation (child received BCG, three doses of oral
polio vaccine (OPV), three doses of DTP and measles
vaccines by one year of age) was only 52% in one region
between 2000 and 2010 [12].
In The Gambia, vaccines are procured by UNICEF and
are delivered by air twice a year, except for Rotavirus
and Pneumococcal Conjugate Vaccine (PCV) which are
delivered quarterly due to their large volumes. Once in
the country, vaccines are stored at the central cold room
and moved every quarter via a push system to the sec-
ond cold room, in rural Gambia and five regional stores
nationwide. Two of the regions without a store collect
vaccines directly from the central cold room (Fig. 1).
In 2016 there were 67 health facilities providing
vaccination services; 32 (47.8%) in urban and periurban
areas. Fourteen out of the 67 facilities (20.9%) were pri-
vate clinics. National EPI wastage projections were 35%
for BCG, 5% for PCV13 and 15% for all other vaccines
in the EPI schedule [13].
Study design
We conducted two observational studies in a total of 18
selected health facilities (all six major health facilities
with 110–150 beds per 150,000–200,000 population and
12 minor health facilities with 20–40 beds per 15,000
population) across rural and urban Gambia. The minor
facilities were randomly selected proportionate to the
total number of minor facilities in each region across the
country (Fig. 1).
Survey 1 - Vaccine wastage in two regions
We purposefully selected two regions for this survey,
West Coast Region (WCR1) and Central River Region
(CRR) in urban and rural Gambia respectively (Fig. 1).
These are the only regions with a cold room. In these re-
gions, we selected the two major health facilities (one
per region) and randomly selected two minor health fa-
cilities (also one per region) (Fig. 1).
Prospective data collection lasted for six months, from
April to September 2016. WHO recommended forms
were used for monitoring of vaccine wastage [6].
Trained study fieldworkers working closely with EPI
personnel, recorded information at each health facility
on the number of children immunised, doses discarded
and the reason, and number of doses opened at each im-
munisation clinic covering both fixed and outreach ses-
sions. At the beginning of each month, the fieldworkers
with the EPI staff did a physical count of the total num-
ber of doses for each vaccine available at the facility. All
data were collated at the end of the month.
Monthly data on doses received, doses issued and dis-
carded were also captured from the two cold rooms in
WCR1 and CRR.
Table 1 Vaccines in The Gambian Immunization schedule, 2016
Formulation Vaccine Vial size
(no. of doses)
Total
doses/child
Schedule
(Months)
Lyophilised BCG 20 1 0
Yellow fever 10 1 9
Measles 10 2 9 & 18
Liquid
(Multi-dose vial)
Hepatitis B 10 1 0
OPV 10 6 0, 2, 3, 4,
9 & 18
Pentavalent 10 3 2, 3 & 4
IPV 10 1 4
DPT 10 1 18
TT 20 Up to 5 Pregnancy
Liquid (Single
dose vial)
PCV 13 1 3 2, 3 & 4
Rotavirus 1 3 2, 3 & 4
MDV Multi-dose vial, BCG Bacillus Calmette–Guérin, OPV Oral Polio vaccine,
DPT Diphtheria - whole cell Pertussis-Tetanus, Pentavalent (2009)- [DPT-Hepatitis
B (1990)- H. influenzae type b (1997)], IPV-Inactivated Polio vaccine (2016), PCV –
pneumococcal conjugate vaccine (PCV7–2009, PCV13–2011)) TT-Tetanus toxoid
given to pregnant women, HPV Human papilloma virus, given to school going
children as part of a demonstration project was not included in this study
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Survey 2 – Knowledge attitude and practice among health
workers nationwide
We conducted a cross sectional survey on the KAP of
health care workers from 18 study facilities across all re-
gions. All health workers engaged in vaccine delivery
were eligible for participation. Health workers were
interviewed on general knowledge on immunisation, and
vaccine waste management using a pre-tested question-
naire. A separate interview was conducted with the
senior officer in charge of EPI in each facility to collect
data on general practices within the facility. The field-
workers were trained not to read out the responses to
questions but rather tick each that applied. At the end of
the interview, the temperature chart and vaccine ledgers
at the facility were inspected to observe the routinely
captured data.
Data analysis
We estimated vaccine wastage rate with 95% confidence
interval for each vaccine included in the Gambia EPI
schedule using the formula; Wastage rate = (Doses used
– Children vaccinated)/ Doses used × 100 at the facility
level. At the storage level, we measured the proportional
wastage rate as number of doses discarded/ (start bal-
ance + number of doses received) × 100 [6].
Types of vaccine waste were described as a proportion
for each vaccine i.e. number of each type of wastage re-
corded (e.g. number of doses discarded from broken
vials) divided by the total number of doses discarded for
that vaccine.
We described the practices at each facility as a per-
centage of the facilities that perform expected activities
and described the KAP of the health workers. For each
response we calculated the proportion that gave the cor-
rect response out of the total number of respondents.
Results
Characteristics of the facilities
All 18 study facilities had fixed base clinics at least once
a month; 13 had between one and four sessions a
month, four had more than one session a week and one
had daily sessions. Outreach sessions occurred in all but
two health facilities, one private and one minor health
facility both in the urban area. The outreach sessions
ranged from one to three times a week. All facilities re-
quested vaccine supplies from their respective Regional
Health Teams (RHT); 72.2% (13/18) on a monthly basis,
ranging from weekly to quarterly.
Vaccine wastage rates and type of wastage
Wastage from cold rooms
56,264 doses of Rotavirus vaccine expired from the cen-
tral cold room (WCR1) and the regional cold room
(CRR) in June 2016, with a proportional wastage rate of
29.4 and 6.7% respectively. There were also a total of
41,460 expired doses of Pentavalent vaccine from the
two cold rooms. The highest proportional wastage rate
was recorded for Yellow Fever (YF) vaccine in CRR due
to breakage of the vaccine diluent, 62.7% (Table 2).
Wastage in health facilities (four facilities)
We found a wide range of vaccine wastage rates depend-
ing on the vaccine or the facility. Vaccine wastage rates
were highest for the lyophilised vaccines BCG, Measles
Fig. 1 EPI collection & distribution system and study sampling framework. WCR West Coast Region, NBW North Bank West, NBE North Bank East,
LRR Lower Region, CRR Central River Region, URR Upper River Region. *facilities with immunisation services, ** two without a store collect directly
from national cold room, *** a second cold room in CRR
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and YF; mean (range) 54.9% (18.5–79.0%), 15.6% (0–
30.9%) and 27.9% (0–55.0%), respectively (Fig. 2 and
Table 3).
For the liquid vaccines for which the MDVP applies,
bivalent OPV (bOPV) had the highest wastage ranging
from 0 to 12.7%, with many doses unaccounted for
(missing). Pentavalent wastage rate was < 1%, except for
one facility that recorded 57.3% due to 160 expired
doses in May 2016. For the other liquid vaccines, both
multi/single dose vials, wastage rates were consistently
low (Fig. 3a and b). PCV13 wastage rate was < 1% in all
facilities during the six months survey.
Although there was a trend of higher rates of wast-
age for lyophilized vaccines in the major health
facilities compared to the minor, this was not statisti-
cally significant (Table 3). There was no statistical
difference between rural and urban facilities for any
vaccine.
For all three lyophilised vaccines, more than 90% of
the wasted doses for each vaccine was due to
remaining doses from open vials that were discarded
at the end of the immunisation session (Table 4). For
liquid vaccines, the type of wastage varied. Rotavirus
vaccines in stock expired in June/July 2016 at all
facilities (Table 5). Other types of wastage recorded in
unopened vials included missing inventory, vaccine
vial monitor (VVM) failure, breakage and use of
wrong diluent, however, these were minimal (Table 5).
There was no record of wastage due to freezing dur-
ing the entire study period.
Table 3 Overall vaccine wastage in major and minor health
facilities (April to September 2016)
Vaccine Average wastage rate (%) P valuea
Overall (95% CI) Major Minor
Lyophilised
BCG 54.9 (47.5–62.2) 50.0 59.7 0.631
Yellow fever 27.9 (21.9–33.9) 23.7 32.3 0.640
Measles 15.6 (11.9–19.3) 10.4 20.8 0.483
Liquid (MDV)
Hep B 1.9 (0.2–3.5) 2.7 1.0 0.765
bOPV 4.4 (2.6–6.2) 6.2 2.6 0.663
Pentavalent 2.5 (−2.4–7.4) 0.13 4.8 0.460
IPV 5.1 (1.4–8.8) 3.2 7.0 0.672
DPT 0.1(−0.2–1.1) 0.9 0 0.747
TT 2.0 (−1.9–5.9) 0.3 3.7 0.548
Liquid (single)
PCV13 0.1 (0.0–0.1) 0.1 0.02 0.945
Rotavirus 5.2 (0.1–10.3) 4.5 5.9 0.878
aMajor versus minor, MDV multi-dose vial, tOPV switched to bOPV from mid-April,
Table 2 Type of vaccine wastage at the cold rooms (April to
September 2016)
Month Vaccine Type of
wastage
Total doses
discarded
Proportionate
wastage (%)
Urban
Apr BCG breakage 40 0.02
Apr Measles breakage 20 0.01
Apr DPT breakage 40 0.10
Apr TT breakage 20 0.01
Apr Pentavalent expiry 40,260 10.7
Jun Rotavirus expiry 55,428 29.4
Rural
Apr Pentavalent expiry 1200 9.6
Jun Rotavirus expiry 836 6.7
Jun BCG missing 240 20.0
Jun YF missing 300 13.8
Aug YF Othera 1010 62.7
abreakage of vaccine diluent
Fig. 2 Wastage rates for Lyophilised vaccines. C01 Urban major, N01
urban minor, L01 Rural major, F01 Rural minor. Red line represents
projected national wastage rate. YF was out of stock in F01 for August
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KAP among health workers from 18 health facilities
Overall there were 82 health workers in the 18 selected
health facilities. All were approached and 80 (97.6%)
were interviewed. The other two travelled from their
base facility and were unable to grant an interview after
three attempts. Most health workers were male within
the 20–29 years age group (73.8%, 59/80) and either
public health officers [PHO] (67.5%, 54/80) or assistant
PHO (25.0%, 25/80).
Almost all the health workers knew that measles vac-
cine had to be discarded after six hours of opening
(93.6%, 73/78). Only 19.0% (15/79) said they would
batch children for BCG vaccination and even less so for
other vaccines. 73.4% (58/79) said they would open a
vaccine according to the MDVP as soon as there was a
request. All participants knew that aseptic conditions
(79/79) were required and 94.9% (75/79) mentioned
that an intact VVM must be in place before reusing a
vaccine (Table 6).
The majority 72.5% (58/80) did not know what EEFO
(‘Earliest expiry first out’) stands for and among those
who said they knew, only 25.9% (n = 15) gave the right
response. Over half 60.6% (47/78) reported that they
knew the national wastage targets, however amongst
Fig. 3 Wastage rates for Liquid vaccines. C01 Urban major, N01 urban minor, L01 Rural major, F01 Rural minor. Red line represents projected
national wastage rate. PCV and Rota single dose vials MDVP does not apply
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these only one person gave the right estimate for all
three vaccines BCG, Pentavalent and Measles as
requested.
Sixty-one (77.2%) interviewees had received training
on vaccine wastage/management with a wide range of
sources of information. The most frequently reported
sources were the EPI/RHT (73.8%, 59/80), others in-
cluded School of Public Health, EPI training manuals,
internet, WHO guidelines, mobile applications, and
monthly staff meetings.
Vaccine stock management at the health facility level (18
health facilities)
The availability of national policy guidelines was con-
firmed by the study staff at each facility. In addition
77.8% of the facilities (14/18) had other training mate-
rials. Vaccines were returned to the cold chain as per the
MDVP. In the majority (14/18) of facilities the officer in
charge reported that wastage was calculated on a
monthly basis, and in the remaining four facilities, it was
calculated either annually (one facility), quarterly (two
facilities), or daily (one facility).
In the six months prior to the survey, cold chain fail-
ures did not occur and vaccine stock out was rare, but
was reported for BCG, OPV and YF for two, three and
four facilities respectively. All facilities except one had a
regular supervisory visit coordinated by the RHT in the
3 months prior to the survey.
Data available from the vaccine stock ledgers showed
that all facilities recorded the dates when vaccines were
received, the names of the vaccines, doses received,
balance in stock and VVM status. The variables least re-
corded were doses returned unused, which was recorded
by only five facilities (27.8%), and vaccines damaged, re-
corded by only three (16.78%).
Discussions
To our knowledge, this is the first prospective study to
show vaccine wastage rates in a GAVI eligible country.
Target wastage rates projected by the national EPI were
met for the liquid vaccines in multi-dose/single vials.
However, for the lyophilised vaccines, targets were only
met at the major urban health facility with the largest
catchment area of the four facilities (target population
150,000).
Wastage rates were highest for BCG. Overall, the rates
were higher than the national target of 35% but within
range of the WHO target of 50% [6, 13]. Vaccine wast-
age for lyophilised vaccines including BCG has been
shown to correlate with the size of the vaccination ses-
sion, as the number of children vaccinated decreases,
the wastage increases because unused doses at the end
of the session are discarded [14, 15]. Wastage in open
vials has also been shown to be related to the vial size,
with larger vials size leading to higher wastage [16]. The
health workers in our study reported not to batch chil-
dren for vaccination, but rather most would ‘open a vial
for every child’ which is in keeping with the high na-
tional BCG coverage and the WHO guidelines [6, 11],
but contrary to the Nigerian experience where vaccina-
tors batch for a lyophilised vaccine [17]. Still, wastage
rates in The Gambia were lower than in Bangladesh [14]
with different size of the vaccination session and similar
to India even though the facilities in India used 10-dose
vials [15, 16, 18] compared to our 20-dose vial. A
UNICEF review of the cost-effectiveness of changing
Table 4 Type of wastage for Lyophilised vaccines
Vaccine hf Number of doses (Actual numbers) Type of vaccine wastage (Percentagesa)
Received Opened Immunised Total wasted Expiry VVM breakage Missing Unused Other
Discard after 6 h
BCG C01 3660 3260 2172 1094 0 0 0 0.3 99.5 0.2
F01 780 800 218 582 0 0 0 0 100 0
L01 1300 1600 543 1057 0 0 0 0 99.7 0.3
N01 820 860 469 411 0 0 4.9 0 95.1 0
Measles C01 5400 5082 5020 230 0 0 0 0 100 0
F01 750 720 579 173 0 0 0 0 94.2 5.8
L01 1360 1660 1451 254 0 0 0 0 100 0
N01 950 770 656 131 0 0 0 0 100 0
Yellow C01 2560 2420 2098 376 0 0 2.7 0 94.7 2.6
fever F01 490 500 291 223 0 0 4.5 0 95.5 0
L01 970 990 650 339 0 0 0 0 97.9 2.1
N01 500 520 431 120 0 0 0 0 91.7 8.3
tOPV switched to bOPV from mid-April, IPV introduced in Apr 2016 during the study, initially 10 dose without VVM, replaced with a 10-dose vial with VMM, others
include spillage, breakage of vaccine diluent etc. hf health facility, apercentage = (number doses wasted in each category/total wasted for that vaccine)X 100
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from a 20-dose vial to a 10-dose vial BCG concluded
that it may be more economical to waste than to reduce
vial size because the given price for a 10-dose vial was
only 2–8% lower than that of a 20-dose vial [19]. More
recent models comparing 10 versus 5-dose vials for
other vaccines have shown that a change to smaller vials
could reduce wastage but this does not necessarily imply
a reduction in costs as other technical reasons such as
higher manufacturing and storage costs need to be taken
into consideration [20, 21].
Our data supports existing evidence that wastage rates
are low for vaccines that follow the MDVP. Wastage rates
Table 5 Type of wastage for Liquid vaccines
Vaccine hf Number of doses (Actual numbers) Type of vaccine wastage (Percentagesa)
Received Opened Immunised Total wasted Expiry VVM breakage Missing Unused Other
MDVP
Hep B C01 2000 1935 2186 116 0 1.7 12.1 86.2 0 0
F01 130 260 246 2 0 100 0 0 0 0
L01 600 610 563 11 0 90.9 0 0 0 9.1
N01 410 490 476 9 0 0 0 0 0 100
bOPV C01 15,600 12,520 11,493 417 0 0 0 73.6 0 26.4
F01 1860 1700 1466 58 0 0 0 25.9 0 74.1
L01 4180 3940 3534 365 0 0 0 53.4 0 46.6
N01 3740 2620 2378 57 0 35.1 0 0 0 64.9
Penta C01 6210 6307 7049 12 0 0 83.3 0 0 16.7
F01 890 680 738 160 100 0 0 0 0 0
L01 2170 1920 1967 2 0 0 0 50 0 50
N01 1500 1480 1600 1 0 0 0 0 0 100
IPV C01 2430 2030 2199 34 0 0 0 88.2 0 11.8
F01 270 280 263 35 5.7 0 0 0 94.3 0
L01 770 710 683 46 0 2.2 0 0 97.8 0
N01 500 550 543 28 0 0 0 0 71.4 28.6
DPT C01 2180 2050 2310 20 0 0 0 100 0 0
F01 270 240 250 0 0 0 0 0 0 0
L01 910 830 826 5 0 0 0 100 0 0
N01 300 270 238 0 0 0 0 0 0 0
TT C01 3540 1890 1780 11 0 0 90.9 0 0 9.1
F01 200 200 198 0 0 0 0 0 0 0
L01 760 680 621 0 0 0 0 0 0 0
N01 1500 420 457 80 0 0 0 100 0 0
MDVP NAa
PCV13 C01 5199 5976 5975 1 0 0 0 0 0 100
F01 840 796 796 0 0 0 0 0 0 0
L01 2061 1968 1968 4 0 0 0 100 0 0
N01 1550 1608 1607 1 0 0 0 0 0 100
N01 3740 2620 2378 57 0 35.1 0 0 0 64.9
Rotavirus C01 8520 7034 7041 762 99.7 0 0 0 0 0.3
F01 894 776 775 70 98.6 0 0 0 0 1.4
L01 2063 1933 1897 77 87.0 0 0 13.0 0 0
N01 1751 1672 1666 202 97.5 0 0 2.5 0 0
tOPV switched to bOPV from mid-April, IPV introduced in Apr 2016 during the study, initially 10 dose without VVM, replaced with a 10-dose vial with VMM, others
include spillage, breakage of vaccine diluent etc. hf health facility, apercentage = (number doses wasted in each category/total wasted for that vaccine)X 100,
MDVP multi-dose vial policy, NA not applicable
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were lower in centres where the MDVP was practised in
Cameroon [22] and Bangladesh [14] compared to those
that do not. Similarly, in urban Indian health facilities,
wastage of OPV reduced by 50% after introducing the
MDVP [23]. The wastage rates reported for the liquid vac-
cines, Pentavalent, bOPV and Hepatitis B in our study
were lower than that from Asian studies [14, 24].
Our study confirms mathematical models showing that
wastage in single dose vials PCV are minimal [7]. PCV13
in 4-dose vial presentation is now available in addition
to the single dose vial [25]. Earlier studies have shown
that for immunisation programmes in developing coun-
tries, while per-dose price of antigens in multi-dose vials
are lower than single-dose vaccines, even moderate
wastage rates can quickly negate this price gain [7, 26].
As the MDVP is applicable to the 4-dose vial, wastage is
expected to be low in countries where it is introduced.
Doses wasted in unopened vials are not acceptable and
should be minimised with better planning [6]. The
observed peaks in wastage rates for the Pentavalent,
Tetanus toxoid and Rotavirus vaccines may be one off
events during our study. Continuous monitoring is
needed to quickly detect unwanted errors that could
compromise the programme. It was reassuring that there
was no wastage due to freezing and doses discarded due
to changes in the VVM were few, perhaps reflecting the
efficiency of the cold chain system with regular super-
visory visits [2]. We noted that bOPV type of wastage
were mainly ‘missing’ or ‘other’ for example spillage
and spitting of the vaccine. This is not surprising as
bOPV is oral and it may be difficult to quantify the
actual number of doses that remain in a vial at the
end of a vaccination session.
The KAP survey showed high general knowledge on
vaccine waste management among PHO in The Gambia.
We did not take into account the time from training
which would have been useful particularly for those who
did not know EEFO and the wastage rates projected
Table 6 Knowledge attitude and practice among health workers
Yes/total
respondents (%)
Q. For how long can an opened measles vial be kept?
2 h 1/78(1.3)
6 h 73/78(93.6)
24 h 3/78(3.8)
Don’t know 1/78(1.3)
Q. Do you batch/group children for any vaccine?
BCG 15/79(19.0)
Hep B 5/79(6.3)
Measles 5/79(6.3)
YF 3/79(3.8)
OPV 3/79(3.8)
Q. For which vaccines does the MDVP apply?
BCG 10/77(13.0)
Hep Ba 51/80(63.8)
OPVa 52/80(65.0)
Rota 2/79(2.5)
Pentaa 64/80(80.0)
IPVa 50/80(62.5)
PCV 3/80(3.75)
Measles 13/80(16.25)
Yellow fever 13/80(16.25)
DTPa 56/80(70.0)
TTa 55/80(68.75)
Q. What do you do to implement MDVP?
Open as soon as requested 58/79(73.4)
Wait for a few children 9/79 (11.4)
Have a min number of children 2/79 (2.5)
Only on certain dates 3/79(3.8)
Others 37/78 (47.4)
Q. Conditions for reuse of vaccines
Expiry date not passed 57/79 (72.2)
Appropriate cold chain conditions 34/79(43.0)
Aseptic technique 79/79(100.0)
VVM 1 or 2 75/79(94.9)
Others (Label intact) 37/78 (47.4)
Q. What reasons for wastage do you know?
Expired 44/79(55.7)
High temp VVM 47/79(59.5)
Freezing 12/70(15.2)
Spillage 19/79(24.1)
Breakage 47/9(59.5)
> 6 h open 28/79(35.4)
Discard after opening 26/79(27.9)
Table 6 Knowledge attitude and practice among health workers
(Continued)
All doses can’t be used 22/79(27.9)
Others 39/79(49.4)
Q. In what ways can vaccine wastage be reduced?
Improve stock Management 50/79(63.3)
Organise sessions 29/79(36.7)
Batch 11/78(14.1)
EEFO 14/79(17.7)
Minimise misuse 21/79(26.6)
Implement MDVP 23/79(29.1)
Others 51/79(64.7)
aMulti-dose vial policy (MDVP) applies, VVM Vaccine vial monitor EEFO earliest
expiry first out
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targets. Regular refresher trainings will assist to improve
their knowledge on ways to reduce wastage.
The main limitation of our study was that the wastage
survey included only two regions of the country, the two
with cold rooms. Though the results may not be
generalizable to the other five regions, it is noteworthy
that the EPI operates similarly in all regions with the
RHT coordinating all vaccination activities. On the con-
trary, by obtaining data from both major and minor
health facilities in rural and urban Gambia we showed a
wide range of wastage rates across different settings. We
conducted the wastage survey prior to the KAP to avoid
changes in attitudes among health workers as this may
have affected reporting and observations of vaccine
wastage, the primary objective of the study.
Conclusion
This operational research shows that, in general, na-
tional targets for vaccine wastage in The Gambia were
consistently met for liquid vaccines in multi-dose/single
vials during the six months of study period. For lyophi-
lised vaccines such as BCG, high wastage rates were
detected from unused doses at the end of immunisation
sessions. Given the generally high coverage of vaccines
in the Gambia, wastage in unopened vials may be con-
sidered acceptable. Extra effort should be made to en-
sure wastage data, which were incomplete at the
facilities are captured routinely. A longer period of
surveillance will detect if the wastage rates from expir-
ation and breakages are a recurrent issue.
The results from our study should prompt new esti-
mates for the global wastage rates. In the era of new and
more expensive vaccines, data on vaccine wastage are
crucial for local vaccine forecasting and to validate
models. We propose studies in different settings to
compare data and contribute to the review of global
vaccine wastage estimates. Moving forward, studies to
assess if the concern of wastage hinders maximum vac-
cine coverage would be helpful.
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